NeurAxis (NRXS) Stock Skyrockets on First-Ever FDA Approval for GI Pain Device
NeurAxis’s Oct. 24, 2025 announcement of FDA 510 clearance for its PENFS device immediately grabbed market attention. The clearance authorizes use in adults for functional abdominal pain associated with FD and nausea, a segment previously lacking any approved device treatmentinvesting.com. Investing.com and other outlets confirm this milestone — noting it’s “the first FDA clearance or approval” for an adult FD treatmentinvesting.com. In pre-market trading on Oct. 24, NRXS shares jumped on the news, reflecting relief that FDA evidence support could be extended to adultsinvesting.com. Management expects this expansion to “drive substantial top-line growth” as the therapy can now reach millions of adult patients along with children.
